Content about Analgesics

WHAT IT MEANS AND WHY IT'S IMPORTANT Drug companies had better take a close look at their portfolios and make sure they aren’t marketing unapproved drugs. Any excuses they might have for making prescription drugs without regulatory approval will go unheeded by Food and Drug Administration officials.

(THE NEWS: FDA shuts down unapproved Glenmark, Konec drugs. For the full story, click here)

Three Food and Drug Administration advisory committees voted on sweeping changes regarding the marketing, merchandising and formulation of acetaminophen products last month, though the proposed changes fell short of pulling combination products containing acetaminophen off the market. This ECRM section covers intricacies of the FDA committees' decision, as well as external analgesics, foot care, PSE regulations and baby care. Click below to download the PDF of "ECRM Health Care."

NEW YORK While the impetus for this multiple advisory committee meeting and the Food and Drug Administration’s working group that first examined this issue had been in the works long before the Obama administration took office — and consequently the new FDA took hold — there has been some concern that an overly zealous agency is placing any shred of safety concern ahead of consumer access — no matter how miniscule that safety risk may be.